Efficacy and safety of oxygen-sparing nasal reservoir cannula for treatment of pediatric hypoxemic pneumonia in Uganda: a pilot randomized clinical trial

Table 4 Change in vital signs and capillary blood gas parameters with OSNRC or SNC over study periods 1 and 2 of crossover RCT

	Period^a,b	OSNRC	SNC	P-value^c
SpO₂ (%)	1	− 1 (− 2 to − 0.75)	−1.5 (− 2.2 to − 1)	0.44
SpO₂ (%)	2	− 1.5 (− 2.8 to − 1)	0 (−1 to 1.2)	0.1
RR (min⁻¹)	1	−2 (− 6 to − 1)	0 (− 7 to 2)	0.7
RR (min⁻¹)	2	2 (2 to 4)	−3 (− 5 to 0.5)	0.1
HR (min⁻¹)	1	−14 (− 16 to − 11)	1 (− 0.25 to 3.5)	0.0086
HR (min⁻¹)	2	3 (−5.2 to 6)	−4 (− 9.8 to 2.8)	0.48
pCO₂ (mm Hg)	1	7.5 (5.2 to 7.9)	7.6 (5 to 9.2)	0.79
pCO₂ (mm Hg)	2	2.2 (1.1 to 3.7)	0.5 (−1.7 to 1.3)	0.11
pH	1	− 0.063 (− 0.073 to − 0.041)	− 0.073 (− 0.11 to − 0.035)	0.44
pH	2	− 0.01 (− 0.018 to − 0.0065)	0.0025 (− 0.0092 to 0.0083)	0.34
Lactate (mmol/L)	1	− 0.48 (− 0.72 to − 0.32)	0.33 (− 0.4 to 0.98)	0.028
Lactate (mmol/L)	2	−0.13 (− 0.15 to 0.13)	0.3 (0.1 to 0.43)	0.18
Base excess (mmol/L)	1	0.5 (0 to 2.2)	0 (0 to 0.25)	0.34
Base excess (mmol/L)	2	0.5 (0 to 1)	−1 (− 1.2 to 0.25)	0.099

Data represent the median (interquartile range)
^aDuring Period 1, patients were treated with OSNRC (Group A, n = 8) or SNC (Group B, n = 8) for 1 hour
^bDuring Period 2, patients were treated with OSNRC (Group B, n = 6) or SNC (Group A, n = 8) for 1 hour
^cRepresents p-value for difference between OSNRC and SNC treatments

ISSN: 1471-2466